Table. Participant Characteristics.
| Characteristic | Participant group | P valuea | |||
|---|---|---|---|---|---|
| All (n = 427) | Infection naive with mRNA-1273 (Moderna) (n = 172) | Infection naive with BNT162b2 (Pfizer-BioNTech) (n = 135) | Previous infection BNT162b2 (Pfizer-BioNTech) (n = 120) | ||
| Age, median (IQR), y | 68 (39-75) | 69 (40-75) | 68 (39-75) | 67 (37-70) | .05 |
| Age group, No. (%) | |||||
| 18-45 | 152 (36) | 55 (32) | 47 (35) | 50 (42) | .20 |
| 65-74 | 168 (39) | 69 (40) | 50 (37) | 49 (41) | |
| >74 | 107 (25) | 48 (28) | 38 (28) | 21 (18) | |
| Sex, No. (%) | |||||
| Men | 228 (53) | 98 (57) | 68 (50) | 62 (52) | .49 |
| Women | 199 (47) | 74 (43) | 67 (50) | 58 (48) | |
| Body mass index, median (IQR)b | 25 (22-27) | 25 (22-27) | 24 (22-27) | 25 (22-29) | .11 |
| First dose injection date, range | February 19 to June 8, 2021 | February 19 to April 16, 2021 | March 10 to May 4, 2021 | March 15 to June 8, 2021 | NA |
Abbreviation: NA, not applicable.
a
Calculated using Kruskal-Wallis rank sum test or Fisher exact test.
b
Calculated as weight in kilograms divided by height in meters squared.